OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
TAIPEI, TAIWAN, Nov 17, 2025 – (ACN Newswire via SeaPRwire.com) – OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated […]






















